Terlipressin demonstrates ‘major advance’ in hepatorenal syndrome treatment

BOSTON — In this exclusive video from The Liver Meeting 2019, Arun Sanyal, MD, professor of medicine at Virginia Commonwealth University, discusses results of the CONFIRM trial, which demonstrated that terlipressin was effective in improving renal function and achieving hepatorenal syndrome reversal in a significant percentage of patients with hepatorenal syndrome type 1.“[Terlipressin] has been used for hepatorenal syndrome elsewhere for a long-time, but is not an approved drug for this indication in the U.S.,” Sanyal, who is an investigator in the CONFIRM trial, toldRead More

Share on facebook
Share on twitter
Share on linkedin